Does school attendance during initial cancer treatment in childhood increase the risk of infection?

Pediatr Blood Cancer. 2013 Aug;60(8):1307-12. doi: 10.1002/pbc.24510. Epub 2013 Mar 21.

Abstract

Background: The present study aimed to investigate the relationship between school attendance and infection requiring antimicrobial treatment in children undergoing treatment for cancer.

Procedure: A national cohort of children aged 7-16 years undergoing cancer treatment was assessed during two observation periods of 19 days each, 1 month (n = 89) and 2.5 months (n = 89) poststart of treatment. Children free from infection at start of each observation period were included. Multivariable logistic regression analyses were performed including factors potentially associated with start of antimicrobial treatment.

Results: Twenty-seven (30%) children started antimicrobial treatment during the first observation period. Factors associated with an increased risk of starting antimicrobial treatment were diagnosed with sarcoma (OR = 24.37, P = 0.002) or non-Hodgkin lymphoma (OR = 17.57, P = 0.025), having neutropenia (OR = 5.92, P = 0.020) and age less than 13 years (OR = 8.54, P = 0.014). During the second observation period, when 20 (22%) children started antimicrobial treatment, the probability of starting treatment was increased in children with neutropenia (OR = 4.25, P = 0.007). There was no statistically significant association between starting treatment for infection and school attendance.

Conclusions: In this study, children attending school while undergoing cancer treatment did not run a higher risk of starting antimicrobial treatment than children absent from school. However, there is a need for further studies evaluating risk of infections in children with ongoing cancer treatment.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Age of Onset
  • Anti-Infective Agents / administration & dosage*
  • Child
  • Cohort Studies
  • Humans
  • Infection Control*
  • Infections* / drug therapy
  • Infections* / epidemiology
  • Infections* / etiology
  • Lymphoma, Non-Hodgkin* / complications
  • Lymphoma, Non-Hodgkin* / drug therapy
  • Lymphoma, Non-Hodgkin* / epidemiology
  • Male
  • Neutropenia / drug therapy
  • Neutropenia / epidemiology
  • Neutropenia / etiology
  • Risk Factors
  • Sarcoma* / complications
  • Sarcoma* / drug therapy
  • Sarcoma* / epidemiology
  • Schools*

Substances

  • Anti-Infective Agents